Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Pancreatic Ductal 1

Interventions

pembrolizumab 39Nivolumab 15Gemcitabine 8spartalizumab 7atezolizumab 7Carboplatin 7Cyclophosphamide 6130-nm albumin-bound paclitaxel 6durvalumab 5Cisplatin 5Bevacizumab 5fludarabine 4budigalimab 4Paclitaxel 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorouracil 4Cetuximab 4Albumin-Bound Paclitaxel 4tislelizumab 3lenvatinib 3cemiplimab 3avelumab 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Irinotecan 3HMPL-013 3Fulvestrant 3Docetaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × EC regimen × Gastrointestinal × Clear all
NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡